Market Size of Antithrombin Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 4.30 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Antithrombin Market Analysis
The antithrombin market is expected to register a CAGR of 4.3% over the forecast period.
The impact of COVID-19 on the antithrombin market was substantial in the initial phase owing to factors such as the closure of manufacturing facilities and research and development activities. However, the increasing use of antithrombin in COVID-19 patients has accelerated the demand for these products within the market. For instance, as per the report published by Acta Haematologica in December 2022, in severe COVID-19 patients, low antithrombin activity is linked to mortality as well as pro-inflammatory and prolonged hypercoagulable states. Antithrombin is a promising therapeutic target for future research in COVID-19 infection because of its anti-thromboinflammatory characteristics and is expected to attain growth in the market over the coming years.
The factors that drive the market include increasing coagulation diseases and open heart surgeries and increasing usage of diagnostic kits using antithrombin. Antithrombin is crucial since it stops excessive blood clotting. Due to the rise in chronic conditions like heart disease and kidney disease, the usage of antithrombin in surgical procedures has increased. Antithrombin is required during surgery to stop blood clots from forming. Hence, an increase in surgical procedures due to chronic diseases and a rise in antithrombin insufficiency have led to an increase in antithrombin demand, which will help the market grow.
For instance, according to the British Heart Foundation's 2022 report, in the United Kingdom, 7.6 million people suffer from heart and circulation conditions. Furthermore, these figures may continue to climb as a result of underlying conditions that affect the heart and circulatory system, an aging and growing population, as well as other factors. Hence, the high burden of heart and circulatory diseases raises the demand for surgical procedures, thereby increasing the usage of antithrombin and is expected to drive the market over the study period.
Furthermore, in December 2022, Octapharma stated that the ATN-06 study is investigating the use of Atenativ, a Plasma-Derived Antithrombin Concentrate, in people with congenital antithrombin deficiency undergoing surgery or childbirth. Thus with new studies on antithrombin deficiency treatments, the demand for antithrombin drugs increases, which is expected to drive the market over the forecast period.
However, the alternative supplements and the high cost of antithrombin therapy are expected to hinder the growth of the market over the forecast period.
Antithrombin Industry Segmentation
As per the scope of the report, antithrombin is a substance in the blood that limits the blood's ability to clot (coagulation) and is the primary inhibitor of thrombin, which is required for the development of blood clots. The Antithrombin Market is segmented by Usage (Therapeutics, Diagnosis, Research, and Others), Source (Human, Recombinant Goat Milk, and Others), Type (Anticoagulant, Antiplatelet, and Thrombolytic Drugs), Route of Administration (Oral and Parenteral), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD million) for the above segments.
| By Usage | |
| Therapeutics | |
| Diagnostics | |
| Research | |
| Other |
| By Source | |
| Human | |
| Recombinant Goat Milk | |
| Others |
| By Type | |
| Anticoagulant | |
| Antiplatelet | |
| Thrombolytic Drugs |
| By Route of Administration | |
| Oral | |
| Parenteral |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Antithrombin Market Size Summary
The antithrombin market is poised for growth, driven by the increasing prevalence of coagulation diseases and the rising number of open-heart surgeries. Antithrombin plays a critical role in preventing excessive blood clotting, making it essential in surgical procedures, especially for patients with chronic conditions like heart and kidney diseases. The market's expansion is further supported by the growing use of diagnostic kits that incorporate antithrombin. The COVID-19 pandemic initially disrupted the market due to manufacturing and research facility closures, but it also spurred demand as antithrombin was found to be beneficial for severe COVID-19 patients. This dual impact has positioned antithrombin as a promising therapeutic target, contributing to the market's anticipated growth.
The Asia-Pacific region is expected to experience significant market growth, fueled by developing countries such as India and China, which are adopting advanced treatment techniques. The increasing elderly population in these regions, coupled with a rise in thrombosis-related diseases, is likely to drive demand for antithrombin treatments. Additionally, ongoing research into antithrombin deficiency is expected to expand the market further. Despite the high cost of antithrombin therapy and the availability of alternative supplements posing challenges, the market remains moderately competitive, with major players like CSL Limited, Grifols SA, and Takeda Pharmaceuticals actively contributing to its development. Collaborations and new product launches, such as Grifols' partnership with Endpoint Health to develop an Antithrombin III therapy, highlight the dynamic nature of the market.
Antithrombin Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Coagulation Diseases and Open Heart Surgeries
-
1.2.2 Increasing Usage of Diagnostic Kits Using Antithrombin
-
-
1.3 Market Restraints
-
1.3.1 Adoption of Alternative Supplements due to High Cost of Antithrombin Therapy
-
-
1.4 Porter Five Forces
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 By Usage
-
2.1.1 Therapeutics
-
2.1.2 Diagnostics
-
2.1.3 Research
-
2.1.4 Other
-
-
2.2 By Source
-
2.2.1 Human
-
2.2.2 Recombinant Goat Milk
-
2.2.3 Others
-
-
2.3 By Type
-
2.3.1 Anticoagulant
-
2.3.2 Antiplatelet
-
2.3.3 Thrombolytic Drugs
-
-
2.4 By Route of Administration
-
2.4.1 Oral
-
2.4.2 Parenteral
-
-
2.5 Geography
-
2.5.1 North America
-
2.5.1.1 United States
-
2.5.1.2 Canada
-
2.5.1.3 Mexico
-
-
2.5.2 Europe
-
2.5.2.1 Germany
-
2.5.2.2 United Kingdom
-
2.5.2.3 France
-
2.5.2.4 Italy
-
2.5.2.5 Spain
-
2.5.2.6 Rest of Europe
-
-
2.5.3 Asia-Pacific
-
2.5.3.1 China
-
2.5.3.2 Japan
-
2.5.3.3 India
-
2.5.3.4 Australia
-
2.5.3.5 South Korea
-
2.5.3.6 Rest of Asia-Pacific
-
-
2.5.4 Middle East and Africa
-
2.5.4.1 GCC
-
2.5.4.2 South Africa
-
2.5.4.3 Rest of Middle East and Africa
-
-
2.5.5 South America
-
2.5.5.1 Brazil
-
2.5.5.2 Argentina
-
2.5.5.3 Rest of South America
-
-
-
Antithrombin Market Size FAQs
What is the current Antithrombin Market size?
The Antithrombin Market is projected to register a CAGR of 4.30% during the forecast period (2024-2029)
Who are the key players in Antithrombin Market?
Octapharma AG, LFB USA, Takeda Pharmaceutical Company Limited, Grifols, S.A and CSL are the major companies operating in the Antithrombin Market.
